J&J Neglects Research In Baby Powder Lawsuit Trial

Healthcare Company Johnson & Johnson continues to dismiss mounting evidence in talcum powder ovarian cancer lawsuits that their baby powder products have shown a strong correlation with an increased risk for contracting ovarian cancer.

Friday, May 13, 2016 - The second talcum powder ovarian cancer lawsuit to be heard before the City of St. Louis Circuit Court finished with the plaintiff being awarded $55 million and Johnson & Johnson again dismissing decades of medical research that have established a link between talcum powder and an increased risk for ovarian cancer. The company claims that it has discovered its own studies that demonstrate the substance shows no strong correlations with ovarian cancer, however the overwhelming amount of evidence presented by talcum powder cancer lawyers representing the plaintiffs have led to two eight-figure decisions found against the health care giant in 2016.

Johnson & Johnson claims that the medical evidence being presented by the baby powder attorneys representing the plaintiffs is not comprehensive enough to outweigh the research it has discovered that finds no link between talcum powder and ovarian cancer. Even though a recent 2016 talcum powder ovarian power study discovered that menopausal variants may have been the cause of research that did not discover a link, the defendants have yet to admit any wrongdoing in their failure to affix a warning label to their baby powder products warning consumers of the ovarian cancer link.

Johnson & Johnson also points to the Food and Drug Administration and the International Agency for Research on Cancer and the lack of an official acknowledgement of a talcum powder ovarian cancer link by those agencies. However, the IARC has claimed that talc is a possible carcinogen, while the FDA hasn't made a full-fledged investigation into the subject as it considers talcum powder a cosmetic that is on the periphery of its administrative duties.

The medical research that is being presenting during Johnson & Johnson's baby powder ovarian cancer lawsuits dates back to the 1970's when studies first began to discover correlations between talc and ovarian cancer. Since then, the research has continued, with the most recent published materials putting the increased risk for someone who regularly used talcum powder contracting ovarian cancer at up to 30 percent. There have also been dissections of ovary tissue removed from patients who were diagnosed with ovarian cancer that reveals talc deposits embedded in the tumors.

Despite Johnson & Johnson's insistence that their talcum powder products are not connected to any ovarian cancer risk, there is a building notion that the baby powder cancer lawsuits may all receive a lump sum settlement if juries continue to hand down enormous awards to plaintiffs bringing their claims to trial. So far, a total of $127 million has been awarded to plaintiffs in talcum powder cancer lawsuits, with two receiving damages and all three to be heard so far winning their hearings.

There are currently more than 1,200 talcum powder cancer lawsuits pending around the country, with more being filed as the news of the most recent trials has been made public. A third trial before the City of St. Louis Circuit Court is scheduled to begin in September, and despite the convincing evidence presented thus far by talcum powder lawyers representing the plaintiffs, it is likely that Johnson & Johnson once against will not acknowledge the medical research suggesting the existence of a strong link between baby powder and an increased risk for ovarian cancer.

Information provided by TalcumPowderCancerLawsuit.com, a website devoted to providing news about talcum powder ovarian cancer lawsuits, as well as medical research and findings.